GlaxoSmithKline's Arexvy vaccine has been approved by the European Union for use in all adults.

On January 26th, GlaxoSmithKline announced that the European Commission has approved its respiratory syncytial virus vaccine Arexvy for adults 18 years and older. The vaccine had previously been approved for adults at increased risk of respiratory syncytial virus infection aged 50 to 59, as well as for those aged 60 and above. GlaxoSmithKline stated that the company is continuing to seek expansion of the indications for its respiratory syncytial virus vaccine in the United States and Japan.